small molecule

NEFFY

EPINEPHRINE

Loss of exclusivityFebruary 2039latest FDA-listed patent expiry
CompanyARS PHARMACEUTICALS OPERATIONS INC

Drug detail

Brand nameNEFFY
Active ingredientEPINEPHRINE
Strength2MG/SPRAY
Dosage formSPRAY
RouteNASAL
ModalitySmall molecule
FDA approvalAugust 2024
Marketing statusRX

Listed patents

PatentExpiresType
12324838February 2039product
11918655February 2039product
11717571February 2039use U-3979
11191838February 2039product
11744895February 2039use U-3979
10682414February 2039use U-3979
10576156February 2038product
11173209February 2038use U-3979

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

NEFFY patent cliff — loss of exclusivity February 2039 | CliffBio